#NeerajAggarwal presents final overall survival from #TALAPRO2 trial - patients w metastatic #prostatecancer lived longer and had improved time to chemo. Only 2 MDS/AML events in entire trial. Supporting the talazoparib-enzalutamide approval. #GU25 @ascocancer.bsky.social